. 2020 Nov 16;63(22):13719–13732. doi: 10.1021/acs.jmedchem.0c01277

Table 2. Differences in Viability of GLC-4 and ABCC1-Overexpressing GLC-4/adr Cells Treated with COTI-2, COTI-NH₂, Fe-COTI-2, Cu-COTI-2, and Triapine for 72 h.

compound	GLC-4 (IC₅₀, μM)^a	GLC-4/adr (IC₅₀, μM)^a	relative resistance^b	ABCC1 substrate^c
COTI-2	0.03 ± 0.01	0.48 ± 0.15	17.3*	YES
Triapine	0.65 ± 0.09	0.57 ± 0.05	0.9^n.s.	NO
COTI-NH₂	3.64 ± 0.39	3.65 ± 0.41	1.0^n.s.	NO
Fe-COTI-2	0.79 ± 0.07	0.80 ± 0.11	1.0^n.s.	NO
Cu-COTI-2	0.02 ± 0.01	0.06 ± 0.02	3.2*	YES

IC₅₀ values were calculated from concentration–response curves measured by the MTT assay. Values are given as mean ± SD of two or three independent experiments, in triplicates.

Relative resistance was calculated by dividing the IC₅₀ values of the resistant GLC-4/adr by those of the parental GLC-4 cells. *p ≤ 0.05; n.s., not significantly different; calculated by one-sample t-test.

Proposed substrate assignment based on data of GLC-4 and SW480 models.

Table 2. Differences in Viability of GLC-4 and ABCC1-Overexpressing GLC-4/adr Cells Treated with COTI-2, COTI-NH2, Fe-COTI-2, Cu-COTI-2, and Triapine for 72 h.

Table 2. Differences in Viability of GLC-4 and ABCC1-Overexpressing GLC-4/adr Cells Treated with COTI-2, COTI-NH₂, Fe-COTI-2, Cu-COTI-2, and Triapine for 72 h.